A Randomized, Open-Label, Phase 3 Study of Pemetrexed plus Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients with

Grants and Contracts Details

StatusFinished
Effective start/end date5/1/107/18/11

Funding

  • Eli Lilly and Company: $7,000.00